Hyperprogressive Disease After Pembrolizumab Treatment in Advanced Epstein-Barr Virus–Associated Gastric Adenocarcinoma With ERBB2 Amplification

Article Tools CASE REPORTS Genomics-Driven Tumor Treatments Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.20.00272 JCO Precision Oncology no. 5 (2021) 370-377. Published online February 9, 2021. PMID: 34994599 Hyperprogressive Disease After Pembrolizumab Treatment in Advanced Epstein-Barr Virus–Associated Gastric Adenocarcinoma With ERBB2 Amplification Sarah Watson , MD, PhD1,2xSarah WatsonSearch for articles by this author; Joanna Cyrta, MD3xJoanna CyrtaSearch for articles by this author; Marine Lefevre, MD4xMarine LefevreSearch for articles by this author; Julien Masliah Planchon , MD, PhD5xJulien Masliah PlanchonSearch for articles by this author; Christophe Louvet, MD, PhD6xChristophe LouvetSearch for articles by this author; Vincent Servois , MD7xVincent ServoisSearch for articles by this author; Pauline Vaflard , MD1xPauline VaflardSearch for articles by this author; François Clément Bidard, MD, PhD8xFrançois Clément BidardSearch for articles by this author; Ivan Bieche, MD, PhD5xIvan BiecheSearch for articles by this author; and Emilie Soularue, MD6xEmilie SoularueSearch for articles by this author Show More 1Institut Curie, PSL Research University, Department of Medical Oncology, Paris, France2Institut Curie, PSL Research University, INSERM U830, Cancer, Heterogeneity, Instability and Plasticity (CHIP), Equipe labellisée par la Ligue Nationale contre le Cancer, Paris, France3Institut Curie, PSL Research University, Department of Pathology, Paris, France4Institut Mutualiste Montsouris, Department of Pathology, Paris, France5Institut Curie, PSL Research University, Department of Genetics, Paris, France6Institut Mutualiste Montsouris, Department of Medical Oncology, Paris, France7Institut Curie, PSL Research University, Department of Radiology, Paris, France8Institut Curie, UVSQ and Paris Saclay University, Saint Cloud, France https://doi.org/10.1200/PO.20.00272 First Page Full Text PDF Figures and Tables © 2021 by American Society of Clinical OncologySUPPORTSupported by funding from the Institut Curie. S.W. was supported by a grant from the Institut National de la Santé et de la Recherche Médicale (INSERM) and the Foundation Bettencourt-Schueller.AUTHOR CONTRIBUTIONSConception and design: Sarah Watson, Christophe LouvetAdministrative support: Sarah Watson, Pauline VaflardProvision of study materials or patients: Sarah Watson, Marine Lefevre, Christophe Louvet, Ivan BiecheCollection and assembly of data: Sarah Watson, Joanna Cyrta, Marine Lefevre, Christophe Louvet, Vincent Servois, Emilie SoularueData analysis and interpretation: Sarah Watson, Joanna Cyrta, Julien Masliah Planchon, Marine Lefevre, Christophe Louvet, Pauline Vaflard, François Clément Bidard, Ivan BiecheManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Christophe LouvetConsulting or Advisory Role: Merck, Servier, Halozyme, AmgenTravel, Accommodations, Expenses: Roche, MerckFrançois Clément BidardConsulting or Advisory Role: Radius HealthSpeakers' Bureau: Amgen, AstraZeneca, RocheResearch Funding: Novartis, Pfizer, Menarini Silicon Biosystems, ProlynxPatents, Royalties, Other Intellectual Property: ESR1 & MSI Detection Techniques (patents)Travel, Accommodations, Expenses: Roche, Amgen, Pfizer, AstraZeneca, Menarini Silicon BiosystemsEmilie SoularueConsulting or Advisory Role: ServierSpeakers' Bureau: Bristol-Myers SquibbNo other potential conflicts of interest were reported.